Stryker names Spencer Stiles President and Chief Operating Officer

Rhea-AI Summary

Stryker (NYSE:SYK) announced Spencer Stiles will become President and Chief Operating Officer effective January 1, 2026. Stiles, a 27-year Stryker veteran and current Group President of Orthopaedics and Spine since 2019, will lead global businesses, strategy, and mergers and acquisitions. Dylan Crotty will be promoted to Group President, Orthopaedics; Crotty has 27 years at Stryker and currently serves as President, Instruments.

The appointments emphasize internal succession, operational continuity, and leadership experience across Orthopaedics, MedSurg, and Neurotechnology.

Positive

• Internal succession: experienced leaders promoted from within
• Stiles to lead global businesses, strategy, and M&A starting Jan 1, 2026
• Continuity in Orthopaedics leadership with Dylan Crotty promotion
• Stiles has 27 years of Stryker experience and led Orthopaedics since 2019

Negative

• None.

News Market Reaction

-0.44%

1 alert

-0.44% News Effect

On the day this news was published, SYK declined 0.44%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Stiles base salary: $1,000,000 Stiles bonus target: 100% of salary Stiles LTI target: $6,000,000 +5 more

8 metrics

Stiles base salary $1,000,000 Annual base salary under new President & COO role

Stiles bonus target 100% of salary Target annual bonus as % of base salary

Stiles LTI target $6,000,000 Recommended long-term incentive grant value

Crotty base salary $700,000 Annual base salary as Group President, Orthopaedics

Crotty bonus target 85% of salary Target annual bonus as % of base salary

Crotty LTI target $3,000,000 Recommended long-term incentive grant value

Effective date January 1, 2026 Effective date for Stiles as President & COO

Tenure at Stryker 27 years Company tenure for both Stiles and Crotty

Market Reality Check

Price: $366.05 Vol: Volume 1,548,041 is sligh...

normal vol

$366.05 Last Close

Volume Volume 1,548,041 is slightly below the 20-day average of 1,656,339, suggesting no outsized trading response ahead of this leadership update. normal

Technical Shares at $352.97 are trading below the 200-day MA of $376.59, indicating a weaker medium-term trend ahead of the management transition.

Peers on Argus

SYK gained 1.31% while key peers like BSX (-1.3%) and MDT (-1.62%) declined, wit...

SYK gained 1.31% while key peers like BSX (-1.3%) and MDT (-1.62%) declined, with EW up only 2.14%. The move appeared more company-specific than part of a broad Medical Devices rally.

Common Catalyst Multiple peers had routine news (dividends, product and strategy updates), but no shared leadership or restructuring theme connected to SYK’s executive appointments.

Historical Context

5 past events · Latest: Dec 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Leadership change	Positive	-0.4%	Veteran executive named President and COO with internal succession in Orthopaedics.
Oct 30	Earnings results	Positive	-3.5%	Strong Q3 growth, margin expansion, and raised 2025 guidance following acquisitions.
Oct 14	Product showcase	Positive	+1.4%	Expanded trauma portfolio and new fixation systems highlighted at industry meeting.
Oct 01	Earnings schedule	Neutral	-1.5%	Announcement of timing and access details for Q3 2025 earnings release and call.
Sep 09	Product launch	Positive	-0.1%	Launch of FDA‑cleared Incompass Total Ankle System for end‑stage ankle arthritis.

Pattern Detected

Recent history shows several positive operational and earnings updates followed by flat-to-negative next-day moves, indicating a tendency for good news—especially earnings and product launches—to be met with muted or contrarian price reactions.

Recent Company History

This announcement continues a pattern of operational developments at Stryker. Over the past few months, the company reported strong Q3 2025 results with higher net sales, expanded margins, and raised full‑year guidance on Oct 30, 2025, yet the stock fell 3.45%. Product and portfolio news, such as the Incompass Total Ankle System launch on Sep 9, 2025, saw little price impact. Today’s internal succession, disclosed in both the press release and a related 8‑K, fits a theme of emphasizing continuity and portfolio expansion rather than transformational shifts.

Market Pulse Summary

This announcement highlights an internal succession, with a long-tenured executive becoming Presiden...

Analysis

This announcement highlights an internal succession, with a long-tenured executive becoming President and COO effective January 1, 2026 and another promoted to Group President, Orthopaedics. The related 8‑K details new base salaries and long‑term incentive targets, underscoring how Stryker ties leadership roles to structured compensation. In context of recent strong Q3 2025 results and portfolio expansion updates, investors may watch how these leaders execute on strategy, acquisitions, and integration over time.

Key Terms

form 144, rsu vesting, options exercise, 401(k) plan

4 terms

form 144 regulatory

"has a Form 144 notice indicating a planned sale of 165 shares"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

rsu vesting financial

"shares were acquired on 03/21/2025 via RSU vesting, with payment made"

RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.

options exercise financial

"shares were acquired on 11/14/2025 via an options exercise, with payment"

Exercising an option is the act of using a contract that gives you the right to buy or sell a specific stock at a set price. For investors, the decision to exercise matters because it turns a paper right into an actual trade — it can create immediate profit or loss, change how many shares are outstanding (which can dilute ownership), affect cash the investor must pay or receive, and trigger tax consequences, much like deciding to redeem a coupon for a fixed-price purchase.

401(k) plan financial

"1,591 shares held indirectly through a 401(k) plan"

A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.

AI-generated analysis. Not financial advice.

Dylan Crotty promoted to Group President, Orthopaedics

Portage, Michighan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today Spencer Stiles has been appointed President and Chief Operating Officer (COO), effective January 1, 2026. In this role, Stiles will lead the company’s global businesses, strategy, and mergers and acquisitions.

“Appointing Spencer President and COO strengthens our ability to sustain high growth and leverage the breadth of our portfolio,” said Kevin Lobo, Chair and CEO, Stryker. “Spencer's deep knowledge of our business and our customers, combined with his leadership and operational execution will help position us well for the future.”

Stiles, a twenty-seven-year Stryker veteran, has served as Group President of Orthopaedics and Spine since 2019. Throughout his career, he has held leadership roles across Orthopaedics as well as MedSurg and Neurotechnology, and has overseen international regions and key supporting functions. He brings a strong track record of performance and is recognized for his strategic vision, collaborative and motivational leadership, and commitment to advancing healthcare through technology.

“I’m honored to step into this role,” said Stiles. “Our customers inspire everything we do; their challenges drive our innovation, and their trust fuels our growth. Alongside our exceptional Stryker team, I’m excited for what’s next as we continue delivering meaningful impact for patients around the world.”

Dylan Crotty will be promoted to succeed Stiles as Group President, Orthopaedics. Crotty, who has spent twenty-seven years with Stryker, currently serves as President, Instruments. During his tenure, Crotty has held roles of increasing responsibility, leading many diverse businesses including roles in Trauma & Extremities and Europe. He is a proven growth champion, known for his strong operational leadership and collaboration.

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

For investor inquiries:
Jason Beach, Vice President, Finance and Investor Relations
at 269-385-2600 or jason.beach@stryker.com

For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer
at 269-385-2600 or kim.montagnino@stryker.com

FAQ

When does Spencer Stiles start as President and COO of Stryker (SYK)?

Spencer Stiles becomes President and COO effective January 1, 2026.

What responsibilities will Spencer Stiles have as Stryker (SYK) President and COO?

He will lead Stryker's global businesses, overall strategy, and mergers and acquisitions.

Who will replace Spencer Stiles as Group President, Orthopaedics at Stryker (SYK)?

Dylan Crotty will be promoted to Group President, Orthopaedics to succeed Stiles.

What experience does Spencer Stiles bring to the COO role at Stryker (SYK)?

Stiles has 27 years at Stryker and has led Orthopaedics and Spine since 2019, plus roles in MedSurg and Neurotechnology.

What is Dylan Crotty's background before becoming Group President, Orthopaedics at Stryker (SYK)?

Crotty has 27 years at Stryker, currently serves as President, Instruments, and has led Trauma & Extremities and European businesses.